Sathyanarayana Shivaprasad H, Spracklin Sarah B, Deharvengt Sophie J, Green Donald C, Instasi Margery D, Gallagher Torrey L, Shah Parth S, Tsongalis Gregory J
The Laboratory for Clinical Genomics and Advanced Technology, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Dartmouth Health, Lebanon, NH 03756, USA.
Dartmouth Cancer Center Phlebotomy, Department of Laboratory Services, Dartmouth Hitchcock Medical Center, Dartmouth Health, Lebanon, NH 03756, USA.
Cells. 2025 Jul 11;14(14):1062. doi: 10.3390/cells14141062.
Circulating cell-free DNA (cfDNA) is an important biomarker for various cancer types, enabling a non-invasive testing approach. However, pre-analytical variables, including sample collection, tube type, processing conditions, and extraction methods, can significantly impact the yield, integrity, and overall quality of cfDNA. This study presents a comprehensive analytical validation of a magnetic bead-based, high-throughput cfDNA extraction system, with a focus on assessing its efficiency, reproducibility, and compatibility with downstream molecular applications. The validation was performed using a range of sample types: synthetic cfDNA spiked into DNA-free plasma, multi-analyte ctDNA plasma controls, Seraseq ctDNA reference material in a plasma-like matrix, extraction specificity controls, residual clinical specimen from patients, and samples from healthy individuals stored at room temperature or 4 °C for up to 48 h to assess stability. Extracted cfDNA was analyzed for concentration, percentage, and fragment size, using the Agilent TapeStation. Variant detection was evaluated using a next-generation sequencing (NGS) assay on the Seraseq ctDNA reference material. The results demonstrated high cfDNA recovery rates, consistent fragment size distribution (predominantly mononucleosomal and dinucleosomal), minimal genomic DNA (gDNA) contamination, and strong concordance between detected and expected variants in reference materials. The workflow also showed robust performance under different study parameters, variable sample conditions, including sample stability and integrity. Together, these findings confirm the efficiency and reliability of the evaluated cfDNA extraction system and underscore the importance of standardized pre-analytical workflows for the successful implementation of liquid biopsy for early cancer detection, therapeutic monitoring, and improved patient outcomes.
循环游离DNA(cfDNA)是多种癌症类型的重要生物标志物,可实现非侵入性检测方法。然而,包括样本采集、试管类型、处理条件和提取方法在内的分析前变量会显著影响cfDNA的产量、完整性和整体质量。本研究对基于磁珠的高通量cfDNA提取系统进行了全面的分析验证,重点评估其效率、可重复性以及与下游分子应用的兼容性。验证使用了一系列样本类型:掺入无DNA血浆中的合成cfDNA、多分析物ctDNA血浆对照、血浆样基质中的Seraseq ctDNA参考物质、提取特异性对照、患者残留临床标本以及在室温或4°C下储存长达48小时的健康个体样本以评估稳定性。使用安捷伦TapeStation分析提取的cfDNA的浓度、百分比和片段大小。使用对Seraseq ctDNA参考物质的下一代测序(NGS)测定法评估变异检测。结果表明cfDNA回收率高、片段大小分布一致(主要是单核小体和双核小体)、基因组DNA(gDNA)污染最小,并且参考物质中检测到的变异与预期变异之间具有高度一致性。该工作流程在不同研究参数、可变样本条件(包括样本稳定性和完整性)下也表现出强大的性能。总之,这些发现证实了所评估的cfDNA提取系统的效率和可靠性,并强调了标准化分析前工作流程对于成功实施液体活检以进行早期癌症检测、治疗监测和改善患者预后的重要性。